Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.

Goodman SG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Harrington RA, Jukema JW, White HD, Zeiher AM, Manvelian G, Pordy R, Poulouin Y, Stipek W, Garon G, Schwartz GG, ODYSSEY OUTCOMES Investigators.

Open source

DOI: 10.1093/ehjcvp/pvae025
Published: 2024-07-01
Container: Eur Heart J Cardiovasc Pharmacother
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/ehjcvp/pvae025,
  title = {Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.},
  author = {Goodman SG and  Steg PG and  Szarek M and  Bhatt DL and  Bittner VA and  Diaz R and  Harrington RA and  Jukema JW and  White HD and  Zeiher AM and  Manvelian G and  Pordy R and  Poulouin Y and  Stipek W and  Garon G and  Schwartz GG and  ODYSSEY OUTCOMES Investigators.},
  year = {2024},
  journal = {Eur Heart J Cardiovasc Pharmacother},
  doi = {10.1093/ehjcvp/pvae025},
  url = {https://doi.org/10.1093/ehjcvp/pvae025}
}

RIS

TY  - JOUR
TI  - Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.
AU  - Goodman SG
AU  -  Steg PG
AU  -  Szarek M
AU  -  Bhatt DL
AU  -  Bittner VA
AU  -  Diaz R
AU  -  Harrington RA
AU  -  Jukema JW
AU  -  White HD
AU  -  Zeiher AM
AU  -  Manvelian G
AU  -  Pordy R
AU  -  Poulouin Y
AU  -  Stipek W
AU  -  Garon G
AU  -  Schwartz GG
AU  -  ODYSSEY OUTCOMES Investigators.
PY  - 2024
JO  - Eur Heart J Cardiovasc Pharmacother
DO  - 10.1093/ehjcvp/pvae025
UR  - https://doi.org/10.1093/ehjcvp/pvae025
ER  -

APA

SG, G., PG, S., M, S., DL, B., VA, B., R, D., RA, H., JW, J., HD, W., AM, Z., G, M., R, P., Y, P., W, S., G, G., GG, S., & Investigators., O. O. (2024). Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.. Eur Heart J Cardiovasc Pharmacother. https://doi.org/10.1093/ehjcvp/pvae025

Source records

europe-pmc · retrieved 2026-09-27T03:59:05.477Z